Latest From Incyte Corp.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Incyte Pharmaceuticals Inc.
- Incyte Genomics Inc.
- North America
- Parent & Subsidiaries
- Incyte Corp.
- Senior Management
Hervé A Hoppenot, MD, Pres. & CEO
David W Gryska, EVP, CFO
Reid M Huber, PhD, EVP, CSO
Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
Steven H Stein, MD, EVP, CMO
- Contact Info
Phone: (302) 498-6700
1801 Augustine Cut-Off
Wilmington, DE 19803
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.